Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 194 articles:
HTML format



Single Articles


    May 2020
  1. QIU LX, Liu YL, Lin W, Liu YR, et al
    Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance.
    Eur J Gastroenterol Hepatol. 2020 May 22. doi: 10.1097/MEG.0000000000001749.
    PubMed     Abstract available


  2. TSAI MC, Chang KC, Yen YH, Wu CK, et al
    Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites.
    Eur J Gastroenterol Hepatol. 2020 May 2. doi: 10.1097/MEG.0000000000001711.
    PubMed     Abstract available


  3. CHEUNGPASITPORN W, Thongprayoon C, Ungprasert P, Wijarnpreecha K, et al
    Hepatitis A hospitalizations among kidney transplant recipients in the United States: nationwide inpatient sample 2005-2014.
    Eur J Gastroenterol Hepatol. 2020;32:650-655.
    PubMed     Abstract available


  4. TANOGLU A
    Clinical utility of mean platelet volume and related scores for assessing the severity of hepatic fibrosis in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2020;32:664-665.
    PubMed    


    April 2020
  5. HINRICHSEN H, Stoehr A, Cornberg M, Klinker H, et al
    Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Eur J Gastroenterol Hepatol. 2020 Apr 25. doi: 10.1097/MEG.0000000000001759.
    PubMed     Abstract available


  6. CHEN D, Wen S, Wu Z, Gu Y, et al
    Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001721.
    PubMed     Abstract available


  7. KUMADA T, Toyoda H, Tada T, Yasuda S, et al
    Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels.
    Eur J Gastroenterol Hepatol. 2020 Apr 10. doi: 10.1097/MEG.0000000000001733.
    PubMed     Abstract available


    March 2020
  8. YU HC, Tseng JC, Lu LY, Hu JC, et al
    Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2020 Mar 20. doi: 10.1097/MEG.0000000000001707.
    PubMed     Abstract available


  9. GONZALEZ-COLOMINAS E, Batlle M, Monge-Escartin I, Duran X, et al
    Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response.
    Eur J Gastroenterol Hepatol. 2020 Mar 16. doi: 10.1097/MEG.0000000000001714.
    PubMed     Abstract available


  10. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2020;32:378-385.
    PubMed     Abstract available


    February 2020
  11. CHEN Y, Cao D, Li C, Zhang P, et al
    A nomogram for discrimination of non-alcoholic fatty liver disease in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2020 Feb 27. doi: 10.1097/MEG.0000000000001691.
    PubMed     Abstract available


  12. PERISETTI A, Laoveeravat P, Inamdar S, Tharian B, et al
    Hepatitis E virus infection in liver transplant recipients: a descriptive literature review.
    Eur J Gastroenterol Hepatol. 2020 Feb 21. doi: 10.1097/MEG.0000000000001682.
    PubMed     Abstract available


  13. HE Z, Chen J, Wang J, Xu L, et al
    Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection.
    Eur J Gastroenterol Hepatol. 2020 Feb 11. doi: 10.1097/MEG.0000000000001698.
    PubMed     Abstract available


    January 2020
  14. ABDELSAMEEA E, Alsebaey A, Abdel-Razek W, Ehsan N, et al
    Elastography and serum markers of fibrosis versus liver biopsy in 1270 Egyptian patients with hepatitis C.
    Eur J Gastroenterol Hepatol. 2020 Jan 15. doi: 10.1097/MEG.0000000000001672.
    PubMed     Abstract available


    December 2019
  15. GAO X, Duan X, Cai H, Hu Y, et al
    The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001662.
    PubMed     Abstract available


  16. HASSANIN TM, Abdelraheem EM, Abdelhameed S, Abdelrazik M, et al
    Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001647.
    PubMed     Abstract available


  17. RAMACHANDRAN J, Kaambwa B, Muller K, Haridy J, et al
    Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience.
    Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001659.
    PubMed     Abstract available


  18. GAO X, Yang HI, Trinh H, Jeong D, et al
    Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2019 Dec 24. doi: 10.1097/MEG.0000000000001639.
    PubMed     Abstract available


  19. LIONS C, Laroche H, Zaegel-Faucher O, Ressiot E, et al
    Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit.
    Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001640.
    PubMed     Abstract available


  20. AL-AZZAWI Y, Albo B, Fasullo M, Coukos J, et al
    Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2019 Dec 9. doi: 10.1097/MEG.0000000000001583.
    PubMed     Abstract available


  21. DARWEESH SK, Yosry A, Salah M, Zayed N, et al
    Acoustic radiation forced impulse-based splenic prediction model using data mining for the noninvasive prediction of esophageal varices in hepatitis C virus advanced fibrosis.
    Eur J Gastroenterol Hepatol. 2019;31:1533-1539.
    PubMed     Abstract available


    November 2019
  22. POYNARD T, Peta V, Deckmyn O, Pais R, et al
    Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001606.
    PubMed     Abstract available


  23. WANG XH, Jiang XM, Gao PX, Liu Q, et al
    Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001574.
    PubMed     Abstract available


  24. SHOUSHA HI, Saad Y, Saleh DA, Dabes H, et al
    Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Nov 25. doi: 10.1097/MEG.0000000000001612.
    PubMed     Abstract available


  25. TOSON EA, Shiha GE, El-Sharkawy AM, El-Mezayen HA, et al
    Diagnostic performance of extrinsic apoptosis pathway in hepatitis C virus patients: apoptosis fibrosis crosstalk.
    Eur J Gastroenterol Hepatol. 2019 Nov 14. doi: 10.1097/MEG.0000000000001603.
    PubMed     Abstract available


  26. SU C, Jin C, Han J, Hu X, et al
    Ultrasonographic assessment of right heart intracardiac mass in patients with hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2019 Nov 8. doi: 10.1097/MEG.0000000000001589.
    PubMed     Abstract available


  27. GOZDAS HT, Ince N
    Elevated mean platelet volume to platelet ratio predicts advanced fibrosis in chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Nov 7. doi: 10.1097/MEG.0000000000001599.
    PubMed     Abstract available


  28. SLIEM HA, Salem AS, Hussien WM, El Sayed HRA, et al
    Arterial wall structural changes in noncirrhotic chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019;31:1432-1438.
    PubMed     Abstract available


  29. WIEGAND J, Buggisch P, Mauss S, Boeker KHW, et al
    Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
    Eur J Gastroenterol Hepatol. 2019;31:1424-1431.
    PubMed     Abstract available


    October 2019
  30. WANG Y, Li XY, Wu LL, Zheng XY, et al
    Dynamic prediction of liver cirrhosis risk in chronic hepatitis B patients using longitudinal clinical data.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001592.
    PubMed     Abstract available


  31. EL-KHAYAT H, Kamal EM, Mahmoud H, Gomaa A, et al
    Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001581.
    PubMed     Abstract available


  32. HEIL J, Soufidi K, Stals F, Frantzen H, et al
    Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001593.
    PubMed     Abstract available


  33. MANOLAKOPOULOS S, Striki A, Papastergiou V, Perlepe N, et al
    Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001558.
    PubMed     Abstract available


  34. TACHI Y, Hirai T, Kojima Y, Tachino H, et al
    Diagnostic performance of real-time tissue elastography in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2019 Oct 30. doi: 10.1097/MEG.0000000000001539.
    PubMed     Abstract available


  35. PAPE S, Nevens F, Verslype C, Mertens C, et al
    Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience.
    Eur J Gastroenterol Hepatol. 2019 Oct 24. doi: 10.1097/MEG.0000000000001580.
    PubMed     Abstract available


  36. FERREIRA G, Stuurman AL, Horsmans Y, Cattaert T, et al
    Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink.
    Eur J Gastroenterol Hepatol. 2019 Oct 22. doi: 10.1097/MEG.0000000000001537.
    PubMed     Abstract available


  37. CHEN PC, Chen BH, Huang CH, Jeng WJ, et al
    Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and sp
    Eur J Gastroenterol Hepatol. 2019;31:1256-1263.
    PubMed     Abstract available


    September 2019
  38. ABBAS OM, Khalifa KAE, Makhlouf MM, Osman NF, et al
    Influence of esophageal variceal bleeding on iron status in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Sep 16. doi: 10.1097/MEG.0000000000001547.
    PubMed     Abstract available


  39. MORALES-ARRAEZ D, Nieto Bujalance Y, Diaz-Flores F, de Vera A, et al
    Risk of liver fibrosis progression in patients with suboptimal diagnosis of hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001534.
    PubMed     Abstract available


  40. MORALES-ARRAEZ D, Diaz-Flores F, Alonso A, de Vera A, et al
    Patients with suboptimal hepatitis B virus diagnostic characterization are at risk of liver fibrosis progression.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001527.
    PubMed     Abstract available


  41. KIM MN, Lee JH, Chon YE, Ha Y, et al
    Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001520.
    PubMed     Abstract available


  42. CHUN HS, Kim BK, Park JY, Kim DY, et al
    Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2019 Sep 3. doi: 10.1097/MEG.0000000000001512.
    PubMed     Abstract available


  43. FAN Y, Zhou S, Li C, Ma B, et al
    The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction.
    Eur J Gastroenterol Hepatol. 2019;31:1167-1168.
    PubMed    


    August 2019
  44. DURCAN E, Hatemi I, Sonsuz A, Canbakan B, et al
    The effect of direct antiviral treatment on the depression, anxiety, fatigue and quality-of-life in chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001501.
    PubMed     Abstract available


  45. CHEN J, Shi X, Luo T, Zhao Y, et al
    The correlations between hepatitis B virus infection and hepatocellular carcinoma with portal vein tumor thrombus or extrahepatic metastasis.
    Eur J Gastroenterol Hepatol. 2019 Aug 20. doi: 10.1097/MEG.0000000000001514.
    PubMed     Abstract available


  46. SARWAR S, Tarique S, Aleem A, Khan AA, et al
    Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
    Eur J Gastroenterol Hepatol. 2019;31:1035-1039.
    PubMed     Abstract available


    July 2019
  47. YU ZJ, Zhang LL, Huang TT, Zhu JS, et al
    Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2019;31:873-877.
    PubMed     Abstract available


  48. HWAN YJ, Shin J, Jin YJ, Lee JW, et al
    Comparison of clinical manifestations and outcomes of noncirrhotic and cirrhotic hepatocellular carcinoma patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Jul 1. doi: 10.1097/MEG.0000000000001478.
    PubMed     Abstract available


    June 2019
  49. GARIOUD A, Heng R, Amiot X, Remy AJ, et al
    Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
    Eur J Gastroenterol Hepatol. 2019 Jun 18. doi: 10.1097/MEG.0000000000001450.
    PubMed     Abstract available


  50. CHEN B, Pang L, Cao H, Wu D, et al
    Autologous stem cell transplantation for patients with viral hepatitis-induced liver cirrhosis: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Jun 14. doi: 10.1097/MEG.0000000000001455.
    PubMed     Abstract available


    May 2019
  51. HANAFY AS, Seleem WM, Basha MAA, Marei AM, et al
    Residual hepatitis C virus in peripheral blood mononuclear cell as a risk factor for hepatocellular carcinoma after achieving a sustained virological response: a dogma or fiction.
    Eur J Gastroenterol Hepatol. 2019 May 29. doi: 10.1097/MEG.0000000000001459.
    PubMed     Abstract available


  52. YUAN X, Duan SZ, Cao J, Gao N, et al
    Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients.
    Eur J Gastroenterol Hepatol. 2019 May 17. doi: 10.1097/MEG.0000000000001437.
    PubMed     Abstract available


  53. WANG H, Wang J, Huang R, Xia J, et al
    Red blood cell distribution width for predicting significant liver inflammation in patients with autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2019 May 16. doi: 10.1097/MEG.0000000000001447.
    PubMed     Abstract available


  54. COSTA M, Rojas Rojas T, Lacoste D, Villes V, et al
    Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
    Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441.
    PubMed     Abstract available


  55. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    Eur J Gastroenterol Hepatol. 2019 May 6. doi: 10.1097/MEG.0000000000001434.
    PubMed     Abstract available


  56. OUBINA JR, Delfino CM, Mathet VL
    Hepatitis D virus infection in patients with hepatitis B virus occult infection.
    Eur J Gastroenterol Hepatol. 2019;31:646.
    PubMed    


    April 2019
  57. CHALOUNI M, Sogni P, Miailhes P, Lacombe K, et al
    Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.
    Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001408.
    PubMed     Abstract available


  58. HAMIDI AA, Oncul A, Ozguven BY, Sevgi DY, et al
    Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2019 Apr 25. doi: 10.1097/MEG.0000000000001428.
    PubMed     Abstract available


  59. SORIANO V, Aguilera A, Gonzalez R, Gomez-Gallego F, et al
    Occult hepatitis B and HIV infection.
    Eur J Gastroenterol Hepatol. 2019 Apr 8. doi: 10.1097/MEG.0000000000001417.
    PubMed     Abstract available


  60. POST G, Shalev N, Baumgarten A, Shimakawa Y, et al
    Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001409.
    PubMed     Abstract available


  61. EMORI CT, Uehara SNO, Carvalho-Filho RJ, Amaral AC, et al
    Changing pattern of chronic hepatitis C in renal transplant patients over 20 years.
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001404.
    PubMed     Abstract available



  62. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy: Erratum.
    Eur J Gastroenterol Hepatol. 2019;31:549.
    PubMed    


  63. ABD-ELSALAM S, Arafa M, Elkadeem M, Elfert A, et al
    Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
    Eur J Gastroenterol Hepatol. 2019;31:499-502.
    PubMed     Abstract available


    March 2019
  64. ILIAZ R, Yuce T, Torun S, Cavus B, et al
    Changing epidemiology of chronic hepatitis C: patients are older and at a more advanced stage at the time of diagnosis.
    Eur J Gastroenterol Hepatol. 2019 Mar 25. doi: 10.1097/MEG.0000000000001406.
    PubMed     Abstract available


  65. FOUAD R, Elsharkawy A, Abdel Alem S, El Kassas M, et al
    Clinical impact of serum alpha-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2019 Mar 20. doi: 10.1097/MEG.0000000000001400.
    PubMed     Abstract available


  66. EL-MAKSOUD MA, Habeeb MR, Ghazy HF, Nomir MM, et al
    Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2019 Mar 11. doi: 10.1097/MEG.0000000000001388.
    PubMed     Abstract available


  67. DARWEESH SK, AbdElAziz RA, Abd-ElFatah DS, AbdElazim NA, et al
    Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2019 Mar 4. doi: 10.1097/MEG.0000000000001385.
    PubMed     Abstract available


  68. MUSHTAQ S, Ghani E, Azam K, Hussain T, et al
    Comparison of chitinase-3-like protein 1, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 index with shear-wave elastography.
    Eur J Gastroenterol Hepatol. 2019;31:357-362.
    PubMed     Abstract available


    February 2019
  69. LIAN MJ, Zhang JQ, Chen SD, Zhang DD, et al
    Diagnostic accuracy of gamma-glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001381.
    PubMed     Abstract available


  70. SANDMANN L, Dorge P, Wranke A, Vermehren J, et al
    Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers.
    Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386.
    PubMed     Abstract available


  71. KOUKOULIOTI E, Brodzinski A, Mihm U, Sarrazin C, et al
    Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections.
    Eur J Gastroenterol Hepatol. 2019 Feb 15. doi: 10.1097/MEG.0000000000001351.
    PubMed     Abstract available


  72. DARWEESH SK, Gad AA, Akroof K, ElLatif ZA, et al
    Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Eur J Gastroenterol Hepatol. 2019 Feb 4. doi: 10.1097/MEG.0000000000001377.
    PubMed     Abstract available


  73. SUAREZ E, Buti M, Rodriguez M, Prieto M, et al
    Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
    Eur J Gastroenterol Hepatol. 2019;31:267-271.
    PubMed     Abstract available


  74. HU Z, Ni P, Fan X, Men R, et al
    Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
    Eur J Gastroenterol Hepatol. 2019;31:277.
    PubMed    


  75. MARCELLIN F, Protopopescu C, Wittkop L, Salmon-Ceron D, et al
    No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Eur J Gastroenterol Hepatol. 2019;31:274-276.
    PubMed    


  76. FAROOQUI MT, Khan MA, Cholankeril G, Khan Z, et al
    Marijuana is not associated with progression of hepatic fibrosis in liver disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2019;31:149-156.
    PubMed     Abstract available


    January 2019
  77. ISMAIL WA, Yousef AE
    Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
    Eur J Gastroenterol Hepatol. 2019 Jan 29. doi: 10.1097/MEG.0000000000001370.
    PubMed     Abstract available


  78. YU JH, Suh YJ, Jin YJ, Heo NY, et al
    Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir.
    Eur J Gastroenterol Hepatol. 2019 Jan 28. doi: 10.1097/MEG.0000000000001357.
    PubMed     Abstract available


  79. EL-KHAYAT H, Kamal EM, Yakoot M, Gawad MA, et al
    Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients.
    Eur J Gastroenterol Hepatol. 2019 Jan 22. doi: 10.1097/MEG.0000000000001360.
    PubMed     Abstract available


  80. ORMECI N, Sezgin O, Karaali R, Aygen B, et al
    Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
    Eur J Gastroenterol Hepatol. 2019 Jan 21. doi: 10.1097/MEG.0000000000001334.
    PubMed     Abstract available


  81. ASHHAB AA, Rodin H, Powell J, Debes JD, et al
    Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA.
    Eur J Gastroenterol Hepatol. 2019;31:24-28.
    PubMed     Abstract available


    December 2018
  82. WU ZX, Chen FS, Zhou XL, Huang Q, et al
    Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.
    Eur J Gastroenterol Hepatol. 2018 Dec 31. doi: 10.1097/MEG.0000000000001345.
    PubMed     Abstract available


  83. HU J, Zhang X, Gu J, Yang M, et al
    Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Dec 12. doi: 10.1097/MEG.0000000000001336.
    PubMed     Abstract available


  84. PONZETTO A, Ciancio A, Figura N
    Delta hepatitis in resolved hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:1528.
    PubMed    


  85. SHEHATA HH, Elfert AA, Abdin AA, Soliman SM, et al
    Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy.
    Eur J Gastroenterol Hepatol. 2018;30:1476-1481.
    PubMed     Abstract available


    November 2018
  86. LYBECK C, Brenndorfer ED, Sallberg M, Montgomery SM, et al
    Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316.
    PubMed     Abstract available


  87. DEMERDASH HM, Elyamany AS, Arida E
    Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001306.
    PubMed     Abstract available


  88. SHAH SM, Baniya JB, Gupta BP, Shrestha A, et al
    Association between liver fibrosis and hepatitis E seroprevalence among HIV-positive individuals in Nepal.
    Eur J Gastroenterol Hepatol. 2018 Nov 5. doi: 10.1097/MEG.0000000000001308.
    PubMed     Abstract available


  89. OZARAS R, Uraz S, Demirel A, Mete B, et al
    Resolved hepatitis B virus infection: an unresolved issue of terminology.
    Eur J Gastroenterol Hepatol. 2018;30:1389.
    PubMed    


    October 2018
  90. SHAHID M, Idrees M, Butt AM, Raza SM, et al
    Hepatitis C and G virus coinfection in Punjab, Pakistan: incidence and its correlation analysis with clinical data.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001302.
    PubMed     Abstract available


  91. LV DD, Wang ML, Chen EQ, Wu DB, et al
    A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001299.
    PubMed     Abstract available


  92. DRIEDGER M, Galanakis C, Doyle MA, Cooper CL, et al
    Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu.
    Eur J Gastroenterol Hepatol. 2018 Oct 30. doi: 10.1097/MEG.0000000000001292.
    PubMed     Abstract available


  93. SHAH T, Hussain W, Ali N, Sardar S, et al
    Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Eur J Gastroenterol Hepatol. 2018 Oct 24. doi: 10.1097/MEG.0000000000001287.
    PubMed     Abstract available


  94. KRUGER K, Krauth C, Rossol S, Mauss S, et al
    Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry.
    Eur J Gastroenterol Hepatol. 2018 Oct 15. doi: 10.1097/MEG.0000000000001283.
    PubMed     Abstract available


  95. IBRAHIM EH, Marzouk SA, Zeid AE, Lashen SA, et al
    Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 2. doi: 10.1097/MEG.0000000000001272.
    PubMed     Abstract available


  96. LI B, Zhang L, Zhang Z, Yan G, et al
    A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 1. doi: 10.1097/MEG.0000000000001281.
    PubMed     Abstract available


  97. VAN SANTEN DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, et al
    High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
    Eur J Gastroenterol Hepatol. 2018;30:1168-1176.
    PubMed     Abstract available


    September 2018
  98. ESSA M, Sabry A, Abdelsameea E, Tharwa ES, et al
    Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Sep 21. doi: 10.1097/MEG.0000000000001250.
    PubMed     Abstract available


  99. ATTIA D, Deterding K, Cornberg J, Gebel MJ, et al
    Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Eur J Gastroenterol Hepatol. 2018 Sep 19. doi: 10.1097/MEG.0000000000001259.
    PubMed     Abstract available


  100. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Abstract available


  101. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Abstract available


  102. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Abstract available


    August 2018
  103. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Abstract available


  104. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Abstract available


  105. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Abstract available


  106. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Abstract available


  107. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Abstract available


    July 2018
  108. SONG BG, Sinn DH, Chi S, Kim K, et al
    Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001226.
    PubMed     Abstract available


  109. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Abstract available


  110. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Abstract available


  111. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Abstract available


  112. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Abstract available


  113. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed    


  114. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed    


  115. COMBA A, Demirbas F, Caltepe G, Eren E, et al
    Retrospective analysis of children with alpha-1 antitrypsin deficiency.
    Eur J Gastroenterol Hepatol. 2018;30:774-778.
    PubMed     Abstract available


    June 2018
  116. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Abstract available


  117. AGUILERA A, Rodriguez-Calvino J, de Mendoza C, Soriano V, et al
    Hepatitis delta in patients with resolved hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2018 Jun 20. doi: 10.1097/MEG.0000000000001187.
    PubMed     Abstract available


  118. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Abstract available


    May 2018
  119. YOON CH, Jin YJ, Lee JW
    Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Eur J Gastroenterol Hepatol. 2018 May 29. doi: 10.1097/MEG.0000000000001174.
    PubMed     Abstract available


  120. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Abstract available


  121. AGUILERA A, Trastoy R, Rodriguez-Calvino J, Manso T, et al
    Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.
    Eur J Gastroenterol Hepatol. 2018 May 8. doi: 10.1097/MEG.0000000000001163.
    PubMed     Abstract available


  122. CHEN B, Wang YH, Qian JQ, Wu DB, et al
    Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 May 3. doi: 10.1097/MEG.0000000000001156.
    PubMed     Abstract available


  123. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Abstract available


  124. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed    


  125. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Abstract available


  126. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Abstract available


    April 2018
  127. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Abstract available


  128. SPAHR L, Goossens N, Furrer F, Dupuis M, et al
    A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001148.
    PubMed     Abstract available


  129. GOKCE O, Ozenirler S, Atak Yucel A, Oruklu N, et al
    Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Apr 20. doi: 10.1097/MEG.0000000000001123.
    PubMed     Abstract available


  130. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Abstract available


  131. SPINICCI M, Emmi G, Dies L, Barilaro A, et al
    Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Eur J Gastroenterol Hepatol. 2018 Apr 11. doi: 10.1097/MEG.0000000000001132.
    PubMed     Abstract available


  132. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Abstract available


  133. EFE C, Ozaslan E, Purnak T
    Second-line immunosuppressants for autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2018;30:490-491.
    PubMed    


  134. PONZETTO A, Figura N
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018;30:490.
    PubMed    


  135. POYNARD T, Munteanu M, Charlotte F, Perazzo H, et al
    Impact of steatosis and inflammation definitions on the performance of NASH tests.
    Eur J Gastroenterol Hepatol. 2018;30:384-391.
    PubMed     Abstract available


    March 2018
  136. TONON M, Piano S, Romano A, Fasolato S, et al
    Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
    Eur J Gastroenterol Hepatol. 2018;30:284-290.
    PubMed     Abstract available


    February 2018
  137. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Abstract available


  138. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Abstract available


  139. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Abstract available


  140. ZHANG Y, Shi Y, Wu R, Wang X, et al
    Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001100.
    PubMed     Abstract available


  141. HUANG R, Zhao XA, Wang J, Hao Y, et al
    Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:241.
    PubMed    


  142. ZHANG X, Qi X, Yoshida EM, Mendez-Sanchez N, et al
    Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes.
    Eur J Gastroenterol Hepatol. 2018;30:233-240.
    PubMed     Abstract available


    January 2018
  143. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Abstract available


  144. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Abstract available


  145. PANG Q, Zhou L, Qu K, Cui RX, et al
    Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Eur J Gastroenterol Hepatol. 2018;30:60-70.
    PubMed     Abstract available


    December 2017
  146. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Abstract available


  147. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Abstract available


  148. DE LEMOS-BONOTTO M, Valle-Tovo C, Costabeber AM, Mattos AA, et al
    A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    Eur J Gastroenterol Hepatol. 2017 Dec 8. doi: 10.1097/MEG.0000000000001019.
    PubMed     Abstract available


  149. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Abstract available


    November 2017
  150. LIN Z, Liang J, Zhu J, Hu C, et al
    Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001023.
    PubMed     Abstract available


  151. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Abstract available


  152. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Abstract available


  153. HUANG R, Wang J, Zhao XA, Xia J, et al
    The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017;29:1314.
    PubMed    


    October 2017
  154. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Abstract available


  155. SIMONETTI G, Gitto S, Golfieri L, Gamal N, et al
    Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000000999.
    PubMed     Abstract available


  156. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Abstract available


  157. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Abstract available


  158. ABDEL-RAZIK A, Mousa N, Zakaria S, Elhelaly R, et al
    New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume.
    Eur J Gastroenterol Hepatol. 2017 Oct 13. doi: 10.1097/MEG.0000000000000982.
    PubMed     Abstract available


  159. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed    


    September 2017
  160. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Abstract available


  161. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Abstract available


  162. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Abstract available


  163. LANG S, Kutting F, Staub A, Schramowski J, et al
    Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Sep 6. doi: 10.1097/MEG.0000000000000977.
    PubMed     Abstract available


  164. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Abstract available


  165. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Abstract available


  166. TRIANTOS C, Kalafateli M, Aggeletopoulou I, Mandellou M, et al
    Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    Eur J Gastroenterol Hepatol. 2017;29:998-1003.
    PubMed     Abstract available


    August 2017
  167. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Abstract available


  168. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Abstract available


  169. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Abstract available


  170. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Abstract available


  171. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Abstract available


    July 2017
  172. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Abstract available


    June 2017
  173. FERNANDES SR, Marques da Costa P, Vitor S, Carvalho JR, et al
    Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2017 Jun 16. doi: 10.1097/MEG.0000000000000926.
    PubMed     Abstract available


  174. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Abstract available


    May 2017
  175. SERIGADO JM, Izzy M, Kalia H
    Novel therapies and potential therapeutic targets in the management of chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000911.
    PubMed     Abstract available


  176. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Abstract available


  177. WANG PC, Wei TY, Tseng TC, Lin HH, et al
    Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000897.
    PubMed     Abstract available


  178. JABLONKA A, Solbach P, Wobse M, Manns MP, et al
    Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015.
    Eur J Gastroenterol Hepatol. 2017 May 10. doi: 10.1097/MEG.0000000000000889.
    PubMed     Abstract available


  179. HUANG R, Xia J, Liu Y, Zhang Z, et al
    Acoustic radiation force impulse in the diagnosis of liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000902.
    PubMed    


  180. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed    


  181. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Abstract available


  182. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Abstract available


  183. IINO C, Shimoyama T, Igarashi T, Aihara T, et al
    Usefulness of the Glasgow-Blatchford score to predict 1-week mortality in patients with esophageal variceal bleeding.
    Eur J Gastroenterol Hepatol. 2017;29:547-551.
    PubMed     Abstract available


  184. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Abstract available


    April 2017
  185. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Abstract available


  186. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Abstract available


  187. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Abstract available


    March 2017
  188. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Abstract available


  189. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed    


  190. MURATORI P, Efe C, Muratori L, Ozaslan E, et al
    Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000870.
    PubMed     Abstract available


  191. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Abstract available


    February 2017
  192. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Abstract available


    January 2017
  193. ZHU S, Waili Y, Qi X, Chen Y, et al
    Lymphocyte-monocyte ratio at admission predicts possible outcomes in patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2017;29:31-35.
    PubMed     Abstract available


  194. PAPADOPOULOS N, Deutsch M, Manolakopoulos S, Bitsi C, et al
    Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017;29:56-60.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: